Catalyst Pharmaceuticals (CPRX) Competitors

$31.40 +0.01 (+0.02%)

As of 02:14 PM Eastern

CPRX vs. ASND, BBIO, AXSM, ELAN, and ARWR

Should you buy Catalyst Pharmaceuticals stock or one of its competitors? MarketBeat compares Catalyst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Catalyst Pharmaceuticals include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Catalyst Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 57.87% compared to Catalyst Pharmaceuticals' net margin of 37.08%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 0 mentions for Catalyst Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Ascendis Pharma A/S	Positive
Catalyst Pharmaceuticals	Neutral

Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus target price of $295.39, indicating a potential upside of 23.31%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.89%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.34	-$258M	$8.67	27.63
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05

Summary

Ascendis Pharma A/S beats Catalyst Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to BridgeBio Pharma?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Catalyst Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05
BridgeBio Pharma	$502.08M	27.48	-$724.93M	-$3.74	N/A

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 12 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 12 mentions for BridgeBio Pharma and 0 mentions for Catalyst Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.86 beat Catalyst Pharmaceuticals' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
BridgeBio Pharma	Positive

Catalyst Pharmaceuticals has a net margin of 37.08% compared to BridgeBio Pharma's net margin of -124.42%. Catalyst Pharmaceuticals' return on equity of 35.76% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, indicating a potential upside of 1.89%. BridgeBio Pharma has a consensus price target of $91.05, indicating a potential upside of 29.24%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

Summary

BridgeBio Pharma beats Catalyst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Axsome Therapeutics currently has a consensus target price of $258.95, indicating a potential upside of 6.64%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.89%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Axsome Therapeutics had 7 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for Axsome Therapeutics and 0 mentions for Catalyst Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.08 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Axsome Therapeutics	Positive
Catalyst Pharmaceuticals	Neutral

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Axsome Therapeutics' net margin of -26.59%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.57	-$183.17M	-$3.73	N/A
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05

Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Summary

Axsome Therapeutics beats Catalyst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Elanco Animal Health had 6 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Elanco Animal Health and 0 mentions for Catalyst Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.89 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Elanco Animal Health	Positive

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Elanco Animal Health's net margin of -4.95%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Elanco Animal Health	-4.95%	7.42%	3.66%

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, suggesting a potential upside of 1.89%. Elanco Animal Health has a consensus price target of $28.55, suggesting a potential upside of 18.88%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05
Elanco Animal Health	$4.72B	2.54	-$232M	-$0.50	N/A

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 1.89%. Arrowhead Pharmaceuticals has a consensus target price of $86.36, suggesting a potential upside of 6.00%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05
Arrowhead Pharmaceuticals	$622.01M	18.45	-$1.63M	-$2.15	N/A

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 0 mentions for Catalyst Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.04 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Arrowhead Pharmaceuticals	Positive

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Catalyst Pharmaceuticals beats Arrowhead Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Catalyst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPRX vs. The Competition

Export

Metric	Catalyst Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.84B	$3.00B	$6.54B	$12.27B
Dividend Yield	N/A	1.80%	2.69%	5.82%
P/E Ratio	18.05	18.60	25.16	24.03
Price / Sales	6.53	478.11	554.14	119.99
Price / Cash	10.74	56.31	44.82	54.51
Price / Book	4.05	4.14	10.80	6.45
Net Income	$214.33M	$64.45M	$3.56B	$337.14M
7 Day Performance	0.02%	1.53%	1.50%	-0.32%
1 Month Performance	0.46%	1.15%	0.93%	0.65%
1 Year Performance	42.30%	23.95%	30.55%	27.90%

Catalyst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPRX Catalyst Pharmaceuticals	2.9117 of 5 stars	$31.41 +0.0%	$32.00 +1.9%	+42.0%	$3.84B	$588.99M	18.05	80
ASND Ascendis Pharma A/S	4.922 of 5 stars	$228.00 -1.2%	$295.39 +29.6%	+35.7%	$14.40B	$814.57M	26.30	1,189	Positive News
BBIO BridgeBio Pharma	3.5215 of 5 stars	$68.92 +4.0%	$91.05 +32.1%	+62.7%	$12.98B	$502.08M	N/A	400
AXSM Axsome Therapeutics	2.244 of 5 stars	$247.85 -1.1%	$258.95 +4.5%	+138.0%	$12.89B	$638.50M	N/A	380	Positive News
ELAN Elanco Animal Health	3.7765 of 5 stars	$23.91 -1.3%	$28.55 +19.4%	+73.7%	$12.10B	$4.72B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ASND, BBIO, AXSM, ELAN, and ARWR

How does Catalyst Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Catalyst Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Catalyst Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ASND, BBIO, AXSM, ELAN, and ARWR

How does Catalyst Pharmaceuticals compare to Ascendis Pharma A/S?

Do institutionals and insiders have more ownership in ASND or CPRX?

Is ASND or CPRX more profitable?

Does the media favor ASND or CPRX?

Which has more volatility & risk, ASND or CPRX?

Do analysts prefer ASND or CPRX?

Which has stronger valuation & earnings, ASND or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to BridgeBio Pharma?

Which has preferable earnings and valuation, CPRX or BBIO?

Do institutionals & insiders believe in CPRX or BBIO?

Which has more volatility and risk, CPRX or BBIO?

Does the media prefer CPRX or BBIO?

Is CPRX or BBIO more profitable?

Do analysts rate CPRX or BBIO?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Do analysts recommend AXSM or CPRX?

Do insiders & institutionals have more ownership in AXSM or CPRX?

Does the media favor AXSM or CPRX?

Is AXSM or CPRX more profitable?

Which has better valuation & earnings, AXSM or CPRX?

Which has more risk and volatility, AXSM or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Does the media refer more to CPRX or ELAN?

Is CPRX or ELAN more profitable?

Do analysts recommend CPRX or ELAN?

Do institutionals and insiders hold more shares of CPRX or ELAN?

Which has stronger valuation and earnings, CPRX or ELAN?

Which has more volatility and risk, CPRX or ELAN?

Summary

How does Catalyst Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Do analysts rate CPRX or ARWR?

Which has stronger valuation and earnings, CPRX or ARWR?

Which has more risk and volatility, CPRX or ARWR?

Do insiders and institutionals believe in CPRX or ARWR?

Does the media refer more to CPRX or ARWR?

Is CPRX or ARWR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools